A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

NCT04632992 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

252

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Unresectable or Metastatic Solid Malignancy

Interventions

DRUG: Entrectinib
DRUG: Inavolisib
DRUG: Alectinib
DRUG: Ipatasertib
DRUG: Atezolizumab
DRUG: Trastuzumab Emtansine
DRUG: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
DRUG: Tucatinib
DRUG: Investigator's Choice of Chemotherapy
DRUG: Paclitaxel
DRUG: Tiragolumab
DRUG: Pralsetinib

Sponsor

Genentech, Inc.